SEARCH

SEARCH BY CITATION

References

  • 1
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 173345.
  • 2
    de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39(Suppl. 1): S325.
  • 3
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 122541.
  • 4
    Keeffe E, Dieterich D, Han S, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clinical Gastroenterology and Hepatology 2004; 2: 87106.
  • 5
    Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 85761.
  • 6
    Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003; 38(Suppl. 1): S90103.
  • 7
    Mutimer D, Feraz-Neto BH, Harrison R, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49: 8603.
  • 8
    Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 19124.
  • 9
    Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 42432.
  • 10
    Ganem D, Schneider RJ. Hepadnaviridae: the viruses and their replication. In: KnipeDM, HowleyPM, GriffinDE, LambRE, MartinMA, RoizmanB, StrausSE, eds. Fields Virology. Philadelphia: Lippincott-Raven, 2001: 292369.
  • 11
    Colonno RJ, Genovesi EV, Medina I et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001; 184: 123645.
  • 12
    Wolters LM, Niesters HG, de Man RA. Nucleoside analogues for chronic hepatitis B. Eur J Gastroenterol Hepatol 2001; 13: 1499506.
  • 13
    Leung N. Nucleoside analogues in the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2000; 15(Suppl.): E5360.
  • 14
    Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51: 5979.
  • 15
    Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000; 32: 13946.
  • 16
    Aguesse-Germon S, Liu SH, Chevallier M, et al. Inhibitory effect of 2′-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrob Agents Chemother 1998; 42: 36976.
  • 17
    Delmas J, Schorr O, Jamard C, et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002; 46: 42533.
  • 18
    Genovesi EV, Lamb L, Medina I, et al. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the Woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998; 42: 320917.
  • 19
    Lin E, Luscombe C, Colledge D, Wang YY, Locarnini S. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1998; 42: 21327.
  • 20
    Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002; 46: 828.
  • 21
    Korba BE, Schinazi RF, Cote P, Tennant BC, Gerin JL. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 2000; 44: 175760.
  • 22
    Peek SF, Cote PJ, Jacob JR, et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 2001; 33: 25466.
  • 23
    Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J Hepatol 1999; 30: 53650.
  • 24
    Mutimer D, Pillay D, Cook P, et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000; 181: 7136.
  • 25
    Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 2003; 39(Suppl. 1): S12432.
  • 26
    Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 2927.
  • 27
    Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001; 21: 24353.
  • 28
    Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 7113.
  • 29
    Tillmann H, Trautwein C, Bock T, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999; 30: 24456.
  • 30
    Chin R, Shaw T, Torresi J, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to ({-})-{beta}-d-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-{beta}-l-Arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45: 2495501.
  • 31
    Delaney WE IV, Edwards R, Colledge D, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45: 170513.
  • 32
    Ono-Nita SK, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103: 163540.
  • 33
    Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 44955.
  • 34
    Wolters LM, Honkoop P, Niesters HG, de Man RA. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene. J Hepatol 1998; 28: 90910.
  • 35
    Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000; 31: 21924.
  • 36
    Xiong X, Flores C, Yang H, Toole J, Gibbs C. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 166973.
  • 37
    Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7: 1615.
  • 38
    Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 7517.
  • 39
    Aye TT, Bartholomeusz A, Shaw T, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 114853.
  • 40
    Seigneres B, Pichoud C, Ahmed SS, Hantz O, Trepo C, Zoulim F. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis 2000; 181: 122133.
  • 41
    Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 71823.
  • 42
    Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 12934.
  • 43
    Walsh KM, Woodall T, Lamy P, Wight DGD, Bloor S, Alexander GJM. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49: 43640.
  • 44
    Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 10713.
  • 45
    McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099105.
  • 46
    Han SH, Kinkhabwala M, Martin P, et al. Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir. Am J Gastroenterol 1998; 93: 22457.
    Direct Link:
  • 47
    Kruger M, Tillmann HL, Trautwein C, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 1996; 2: 25362.
  • 48
    Lau GK, Liang R, Wu PC, Lee CK, Lim WL, Au WY. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. J Hepatol 1998; 28: 35968.
  • 49
    Manns MP, Neuhaus P, Atkinson GF, et al. Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study. Transpl Infect Dis 2001; 3: 1623.
  • 50
    Rayes N, Seehofer D, Bechstein WO, et al. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin Transplant 1999; 13: 44752.
  • 51
    Rayes N, Neuhaus R, Naumann U, et al. Treatment of hepatitis B-reinfection or de novo-infection after liver transplantation with famciclovir – how effective is it? Transplant Proc 1999; 31: 4812.
  • 52
    Wedemeyer H, Boker KH, Pethig K, et al. Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. Transplantation 1999; 68: 150311.
  • 53
    Lin E, Luscombe C, Wang YY, Shaw T, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996; 40: 4138.
  • 54
    Nicoll A, Locarnini S, Chou ST, Smallwood R, Angus P. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo. J Gastroenterol Hepatol 2000; 15: 30410.
  • 55
    Korba BE, Cote P, Hornbuckle W, Schinazi R, Gerin JL, Tennant BC. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. Antiviral Res 2000; 45: 1932.
  • 56
    Shaw T, Mok S, Locarnini S. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996; 24: 9961002.
  • 57
    de Man RA, Marcellin P, Habal F, et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000; 32: 4137.
  • 58
    Main J, Brown JL, Howells C, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3: 2115.
  • 59
    Trepo C, Jezek P, Atkinson G, Boon R, Young C. Famciclovir in chronic hepatitis B: results of a dose-finding study. J Hepatol 2000; 32: 10118.
  • 60
    Gunther S, von Breunig F, Santantonio T, et al. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol 1999; 30: 74954.
  • 61
    Lai CL, Yuen MF, Hui CK, Garrido-Lestache S, Cheng CT, Lai YP. Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy. J Med Virol 2002; 67: 3348.
  • 62
    Lackner H, Moser A, Benesch M, et al. Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy. J Clin Virol 2002; 25(Suppl. 3): S739.
  • 63
    Lau GK, Nanji A, Hou J, et al. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J Viral Hepat 2002; 9: 2807.
  • 64
    Hultgren C, Weiland O, Milich DR, Sallberg M. Cell-mediated immune responses and loss of hepatitis B e-antigen (HBeAg) during successful lamivudine and famciclovir combination therapy for chronic replicating hepatitis B virus infection. Clin Infect Dis 1999; 29: 15757.
  • 65
    Lau GK, Tsiang M, Hou J, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000; 32: 3949.
  • 66
    Wolters LM, Hansen BE, Niesters HG, de Man RA. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. Eur J Gastroenterol Hepatol 2002; 14: 100711.
  • 67
    Sangfelt P, Uhnoo I, Hollander A, Lindh G, Weiland O. Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: a pilot study. Scand J Infect Dis 2002; 34: 50511.
  • 68
    Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl 2002; 8: 29.
  • 69
    Gilson RJ, Chopra KB, Newell AM, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6: 38795.
  • 70
    Heathcote EJ, Jeffers L, Perrillo R, et al. Serum HBV DNA suppression and seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B patients. Hepatology 2001; 34(4 Part 2): 316A.
  • 71
    Marcellin P, Chang TT, Lim SG, et al. GS-98–437 a double-blind, randomised, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. Hepatology 2001; 34(4 Part 2): 340A.
  • 72
    Korba BE, Cote P, Hornbuckle W, Tennant BC, Gerin JL. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 2000; 31: 116575.
  • 73
    Cullen JM, Li DH, Brown C, et al. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 2001; 45: 27405.
  • 74
    Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000; 44: 55160.
  • 75
    Mutimer D, Hann H-WL, Buti M, et al. Significant clinical improvement following the addition of adefovir dipivoxil to lamivudine in decompensated patients with YMDD variant HBV and a reduced response to lamivudine – 1 year results. Hepatology 2002; 36(4 Part 2): 625A.
  • 76
    Schiff E, Lai CL, Neuhaus P, et al. Adefovir dipivoxil (ADV) for the treatment of chronic hepatitis B in patients pre- and post-liver transplantation (OLT) with lamivudine-resistant (LAM-R) hepatitis B virus (HBV) patients. Hepatology 2002; 36(4 Part 2): 371A.
  • 77
    Benhamou Y, Bochet M, Thibault V, et al. An open label pilot study of the safety and efficacy of adefovir dipivoxil in HIV/HBV co-infected patients with lamivudine resistant HBV. Hepatology 2000; 32(4 Part 2): 459A.
  • 78
    Benhamou Y, Bochet M, Thibault V, et al. 96 Week efficacy and safety of adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in chronic hepatitis B patients co-infected with HIV. Hepatology 2002; 36(4 Part 2): 638A.
  • 79
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 8007.
  • 80
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 81
    Hadziyannis S, Tassopoulos NC, Heathcote EJ, et al. Long-term (96 weeks) adefovir dipivoxil in HBeAg negative chronic hepatitis results in significant virological, biochemical and histological improvement. Hepatology 2003; 38(4 Suppl 1): 273A.
  • 82
    Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 141927.
  • 83
    Delaugerre C, Marcelin AG, Thibault V, et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002; 46: 15868.
  • 84
    Qi X, Snow A, Thibault V, et al. Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) Patients After 144 Weeks of Therapy. J. Hepatol. 2004; 40(Suppl 1): 201.
  • 85
    Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999; 43: 1903.
  • 86
    Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998; 42: 32008.
  • 87
    Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 18318.
  • 88
    Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46: 252532.
  • 89
    Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41: 14448.
  • 90
    Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002; 37: 13744.
  • 91
    Chang TT, Hadziyannis SJ, Cianciara J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology 2002; 36(4 Part 2): 300A.
  • 92
    Shakil AO, Lilly L, Angus P, et al. Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for hepatitis B. Hepatology 2001; 34(4 Part 2): 619A.
  • 93
    Tassopoulos NC, Hadziyannis SJ, Cianciara J, et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology 2001; 34(4 Part 2): 340A.
  • 94
    Rosmawati M, Lai CL, Lao-Tan J, Sherman M, Thomas N, DeHertogh DA. Entecavir is highly effective in reducing viral load regardless of baseline ALT status. Hepatology 2002; 36(4 Part 2): 623A.
  • 95
    de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34: 57882.
  • 96
    Colonno RJ, Rose R, Cross A, Hindes R, Tenney D. Absence of entecavir resistance emergence in lamivudine-refractory patients treated for at least one year with entecavir in study AI463-014. J. Hepatol. 2004; 40(Suppl. 1): 16.
  • 97
    Condreay LD, Condreay JP, Jansen RW, Paff MT, Averett DR. (−)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrob Agents Chemother 1996; 40: 5203.
  • 98
    Condreay LD, Jansen RW, Powdrill TF, et al. Evaluation of the potent anti-hepatitis B virus agent (−) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model. Antimicrob Agents Chemother 1994; 38: 6169.
  • 99
    Cullen JM, Smith SL, Davis MG, et al. In vivo antiviral activity and pharmacokinetics of (−)-cis-5-fluoro-1- [2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 1997; 41: 207682.
  • 100
    Gish RG, Leung NWY, Wright TL, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46: 173440.
  • 101
    Gish RG, Leung N, Wang C, et al. Antiviral activity, safety and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years. Hepatology 2002; 36(4 Part 2): 372A.
  • 102
    Leung N, Gish RG, Wang C, et al. A randomised, double-blind comparison of 3 doses of emticitabine (FTC) in patients with chronic hepatitis B given 48 weeks of treatment (FTCB-102). Hepatology 2001; 34(4 Part 2): 349A.
  • 103
    Das K, Xiong X, Yang H, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75: 47719.
  • 104
    Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5- methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother 1996; 40: 3806.
  • 105
    Chu CK, Ma T, Shanmuganathan K, et al. Use of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39: 97981.
  • 106
    Witcher JW, Boudinot FD, Baldwin BH, et al. Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil in woodchucks. Antimicrob Agents Chemother 1997; 41: 21847.
  • 107
    Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36: 71022.
  • 108
    Marcellin P, Sereni D, Sacks S, et al. Anti-HBV activity and tolerability of clevudine, a novel nucleoside analogue: initial results of a phaseI/II 28-day study. Hepatology 2001; 34(4 Part 2): 320A.
  • 109
    Fu L, Liu SH, Cheng YC. Sensitivity of L-(−)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999; 57: 13519.
  • 110
    Yamamoto T, Litwin S, Zhou T, et al. Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J Virol 2002; 76: 121323.
  • 111
    Bryant ML, Bridges EG, Placidi L, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45: 22935.
  • 112
    Lai CL, Leung N, Teo EK, et al. Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B. Hepatology 2003; 38(4 Suppl. 1): 262A.
  • 113
    Delaney WE, Yang H, Westland CE, et al. In vitro cross-resistance testing of adefovir, entecavir, and b-L-thymidine against drug-resistant strains of HBV. Hepatology 2001; 34(4 Part 2): 628A.
  • 114
    Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat 2000; 7: 7983.
  • 115
    Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348: 1778.
  • 116
    Nunez M, Garcia-Samaniego J, Perez-Olmeda M, Romero M, Rios P, Soriano V. Therapy with tenofovir in HBV/HIV co-infected patients with resistance or partial response to lamivudine. Hepatology 2002; 36(4 Part 2): 636A.
  • 117
    Park J, Braun J, Kreiswirth S, Goldman D, Mullen M, Dieterich D. Co-infection With HIV and HBV: the effect of tenofovir disoproxil fumarate in lamivudine and famciclovir experienced patients. Hepatology 2002; 36(4 Part 2): 641A.
  • 118
    Piliero PJ, Faragon JJ. Case report. Hepatitis B virus and HIV coinfection. AIDS Read 2002; 12: 44351.
  • 119
    Van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36: 5078.
  • 120
    Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186: 18447.
  • 121
    Cecil BD. Tenofovir 300 mg daily is effective in patients with chronic HBV who fail lamivudine. Hepatology 2002; 36(4 Part 2): 630A.
  • 122
    Van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124: 5867.
  • 123
    Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004; 18: 9603.
  • 124
    Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1996; 29: 4951.
  • 125
    Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001; 35: 40611.
  • 126
    Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 5628.
  • 127
    Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38: 81826.
  • 128
    Schalm SW. Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence. J Hepatol 2001; 35: 41920.
  • 129
    Tatulli I, Francavilla R, Rizzo GL, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001; 35: 80510.
  • 130
    Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36: 799804.
  • 131
    Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298305.
  • 132
    Janssen HL, Senturk H, Zeuzem S, et al. Peginterferon Alfa-2B and lamivudine combination therapy compared with peginterferon alfa-2B for chronic HBeAg-positive hepatitis B: a randomised controlled trial in 307 Patients. Hepatology 2003; 38: 1323.
  • 133
    Marcellin P, Lau GK, Bonino F, et al. A phase III partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40 kd)(Pegasys) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe positive chronic hepatitis B. Hepatology 2003; 38(4 Suppl. 1): 724A5A.
  • 134
    Sung J, Chan H, Hui A, et al. Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B – a randomised trial. J. Hepatol. 2003; 38(Suppl. 1): 33.
  • 135
    Chan H, Leung N, Hui A, et al. A randomised trial of peginterferon alfa-2B and lamivudine combination treatment versus lamivudine monotherapy in Chinese patients with HBeAg-positive chronic hepatitis B. J. Hepatol. 2004; 40(Suppl. 1): 1256.
  • 136
    Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 21625.
  • 137
    Sung J, Lai J, Zeuzem S, et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003; 38(Suppl. 1): 256.
  • 138
    Lada O, Benhamou Y, Valantin M, et al. In vitro susceptibility of wild-type and lamivudine-resistant hepatitis B virus to tenofovir and adefovir. Hepatology 2003; 38(4 Suppl. 1): 717A.
  • 139
    Benhamou Y, Poynard T. Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. J Hepatol 2003; 39(Suppl. 1): S1949.
  • 140
    Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125: 70512.
  • 141
    Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180: 60713.
  • 142
    Thibault V, Benhamou Y, Seguret C, et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999; 37: 30136.
  • 143
    Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 13026.
  • 144
    Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002; 122: 2445.
  • 145
    Bruno R, Sacchi P, Malfitano A, Filice G. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology 2001; 121: 10278.
  • 146
    Benhamou Y, Piketty C, Katlama C, et al. Efficacy of tenofovir disoproxil fumarate (TDF) for hepatitis B in HIV infected patients. Hepatology 2003; 38(4 Suppl. 1): 712A3A.
  • 147
    Van Bommel F, Wunsche T, Schurmann D, et al. Tenofovir effectively inhibits viral replication in different patient groups with lamivudine-resistant HBV infection. J. Hepatol. 2003; 38(Suppl. 1): 27.
  • 148
    Benhamou Y, Thibault V, Vig P, et al. Long term treatment with adefovir dipivoxil (ADV) for three years in patients with lamivuidine-resistant (LAM-R) HBV and HIV co-infection results in significant and sustained clinical improvement. Hepatology 2003; 38(4 Suppl. 1): 714A.
  • 149
    McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 1987; 7: 71923.
  • 150
    Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 7613.
  • 151
    Bortolotti F. Treatment of chronic hepatitis B in children. J Hepatol 2003; 39(Suppl 1): S2005.
  • 152
    Sokal EM, Roberts EA, Mieli-Vergani G, et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000; 44: 5907.
  • 153
    Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 170613.
  • 154
    Sokal EM, Mizerski J, Woynarowski M, et al. An extended, stratified, follow-on study in children with chronic hepatitis B (CHB) who have completed previous lamivudine studies. Hepatology 2003; 38(4 Suppl. 1): 710A1A.
  • 155
    Lobritto SJ, Harren P, Sims Y, Brown RS. Combination therapy using interferon and lamivudine in pediatric patients. Hepatology 2003; 38(4 Suppl. 1): 721A.
  • 156
    Perrillo RP. Management of the patient with hepatitis B virus-related cirrhosis. J Hepatol 2003; 39(Suppl. 1): S17780.
  • 157
    Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 20710.
  • 158
    Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 41116.
  • 159
    Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 71927.